Literature DB >> 27255164

Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup.

Jen-Chieh Lee1, Tzu-Pin Lu2, Chun A Changou3,4, Cher-Wei Liang1, Hsien-Neng Huang1,5, Alexandra Lauria6, Hsuan-Ying Huang7, Chin-Yao Lin8, Ying-Cheng Chiang9,10, Ben Davidson11,12, Ming-Chieh Lin1, Kuan-Ting Kuo1.   

Abstract

Müllerian adenosarcomas are malignant gynecologic neoplasms. Advanced staging and sarcomatous overgrowth predict poor prognosis. Because the genomic landscape remains poorly understood, we conducted this study to characterize the genomewide copy number variations in adenosarcomas. Sixteen tumors, including eight with and eight without sarcomatous overgrowth, were subjected to a molecular inversion probe array analysis. Copy number variations, particularly losses, were significantly higher in cases with sarcomatous overgrowth. Frequent gains of chromosomal 12q were noted, often involving cancer-associated genes CDK4 (six cases), MDM2, CPM, YEATS4, DDIT3, GLI1 (five each), HMGA2 and STAT6 (four), without association with sarcomatous overgrowth status. The most frequent losses involved chromosomes 13q (five cases), 9p, 16q and 17q (four cases each) and were almost limited to cases with sarcomatous overgrowth. MDM2 and CDK4 amplification, as well as losses of RB1 (observed in two cases) and CDKN2A/B (one case), was verified by FISH. By immunohistochemistry, all MDM2/CDK4-coamplified cases were confirmed to overexpress both encoded proteins, whereas all four cases with (plus an additional four without) gain of HMGA2 overexpressed the HMGA2 protein. Both cases with RB1 loss were negative for the immunostaining of the encoded protein. Chromothripsis-like copy number profiles involving chromosome 12 or 14 were observed in three fatal cases, all of which harbored sarcomatous overgrowth. With whole chromosome painting and deconvolution fluorescent microscopy, dividing tumor cells in all three cases were shown to have scattered extrachromosomal materials derived from chromosomes involved by chromothripsis, suggesting that this phenomenon may serve as visual evidence for chromothripsis in paraffin tissue. In conclusion, we identified frequent chromosome 12q amplifications, including loci containing potential pharmacological targets. Global chromosomal instability and chromothripsis were more frequent in cases with sarcomatous overgrowth. To our knowledge, this is the first time that evidence of chromothripsis has been demonstrated in paraffin-embedded clinical tissues and in adenosarcomas.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27255164     DOI: 10.1038/modpathol.2016.99

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  43 in total

1.  An endometrial polyp with a rearrangement of HMGI-C underlying a complex cytogenetic rearrangement involving chromosomes 2 and 12.

Authors:  S Bol; S Wanschura; B Thode; U Deichert; W J Van de Ven; S Bartnitzke; J Bullerdiek
Journal:  Cancer Genet Cytogenet       Date:  1996-08

2.  Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes.

Authors:  Jan J Molenaar; Jan Koster; Danny A Zwijnenburg; Peter van Sluis; Linda J Valentijn; Ida van der Ploeg; Mohamed Hamdi; Johan van Nes; Bart A Westerman; Jennemiek van Arkel; Marli E Ebus; Franciska Haneveld; Arjan Lakeman; Linda Schild; Piet Molenaar; Peter Stroeken; Max M van Noesel; Ingrid Ora; Evan E Santo; Huib N Caron; Ellen M Westerhout; Rogier Versteeg
Journal:  Nature       Date:  2012-02-22       Impact factor: 49.962

3.  Müllerian adenosarcoma of the uterus. A clinicopathologic analysis of ten cases of a distinctive type of müllerian mixed tumor.

Authors:  P B Clement; R E Scully
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

4.  Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients.

Authors:  Florence Magrangeas; Hervé Avet-Loiseau; Nikhil C Munshi; Stéphane Minvielle
Journal:  Blood       Date:  2011-05-31       Impact factor: 22.113

5.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers.

Authors:  Scott L Carter; Aron C Eklund; Isaac S Kohane; Lyndsay N Harris; Zoltan Szallasi
Journal:  Nat Genet       Date:  2006-08-20       Impact factor: 38.330

6.  Müllerian adenosarcomas of the uterus with sarcomatous overgrowth. A clinicopathological analysis of 10 cases.

Authors:  P B Clement
Journal:  Am J Surg Pathol       Date:  1989-01       Impact factor: 6.394

7.  Uterine adenosarcoma with sarcomatous overgrowth versus uterine carcinosarcoma: comparison of treatment and survival.

Authors:  T C Krivak; J D Seidman; J W McBroom; P J MacKoul; L M Aye; G S Rose
Journal:  Gynecol Oncol       Date:  2001-10       Impact factor: 5.482

Review 8.  Cyclin D-dependent kinases, INK4 inhibitors and cancer.

Authors:  Sagrario Ortega; Marcos Malumbres; Mariano Barbacid
Journal:  Biochim Biophys Acta       Date:  2002-03-14

9.  Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism.

Authors:  S Pemble; K R Schroeder; S R Spencer; D J Meyer; E Hallier; H M Bolt; B Ketterer; J B Taylor
Journal:  Biochem J       Date:  1994-05-15       Impact factor: 3.857

10.  Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins.

Authors:  H Matsushime; M E Ewen; D K Strom; J Y Kato; S K Hanks; M F Roussel; C J Sherr
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

View more
  7 in total

1.  Abnormal expression of YEATS4 associates with poor prognosis and promotes cell proliferation of hepatic carcinoma cell by regulation the TCEA1/DDX3 axis.

Authors:  Song You; Fuqiang Wang; Qing Hu; Pengtao Li; Changmao Zhang; Yaqi Yu; Yi Zhang; Qiu Li; Qing Bao; Pingguo Liu; Jie Li
Journal:  Am J Cancer Res       Date:  2018-10-01       Impact factor: 6.166

2.  Uterine Adenosarcoma with Sarcomatous Overgrowth and Rhabdoid Features: A Rare Case.

Authors:  Sameera Rashid; Mohammed Akhtar
Journal:  Saudi J Med Med Sci       Date:  2022-01-17

Review 3.  [Endometrial and other rare uterine sarcomas : Diagnostic aspects in the context of the 2020 WHO classification].

Authors:  Doris Mayr; Lars-Christian Horn; Grit Gesine Ruth Hiller; Anne Kathrin Höhn; Elisa Schmoeckel
Journal:  Pathologe       Date:  2022-04-01       Impact factor: 1.011

4.  Characterization of FN1-FGFR1 and novel FN1-FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors.

Authors:  Jen-Chieh Lee; Sheng-Yao Su; Chun A Changou; Rong-Sen Yang; Keh-Sung Tsai; Michael T Collins; Eric S Orwoll; Chung-Yen Lin; Shu-Hwa Chen; Shyang-Rong Shih; Cheng-Han Lee; Yoshinao Oda; Steven D Billings; Chien-Feng Li; G Petur Nielsen; Eiichi Konishi; Fredrik Petersson; Thomas O Carpenter; Kesavan Sittampalam; Hsuan-Ying Huang; Andrew L Folpe
Journal:  Mod Pathol       Date:  2016-07-22       Impact factor: 7.842

5.  A Single-Centre Experience on the Management of Adenosarcoma: A Successful Report of an Integrated Medical and Surgical Approach.

Authors:  Myriam Anna Perrone; Margherita Nannini; Giulia Dondi; Donatella Santini; Antonio De Leo; Angelo Paolo Dei Tos; Claudio Zamagni; Maristella Saponara; Lidia Gatto; Concetta Nigro; Paola Bertaccini; Maurizio Zompatori; Pierandrea De Iaco; Anna Myriam Perrone; Maria Abbondanza Pantaleo
Journal:  Clin Med Insights Oncol       Date:  2018-06-18

6.  Whole-Genome Sequencing and Target Validation Analysis of Müllerian Adenosarcoma: A Tumor With Complex but Specific Genetic Alterations.

Authors:  Yanli Ban; Jean V Fischer; Kruti P Maniar; Haiyang Guo; Chang Zeng; Yinuo Li; Qing Zhang; Xinkun Wang; Wei Zhang; Serdar E Bulun; Jian-Jun Wei
Journal:  Front Oncol       Date:  2020-04-15       Impact factor: 6.244

Review 7.  Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.

Authors:  Seiichi Mori; Osamu Gotoh; Kazuma Kiyotani; Siew Kee Low
Journal:  J Hum Genet       Date:  2021-06-07       Impact factor: 3.172

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.